Review of ovarian cancer treatments including olaparib, bevacizumab, and durvalumab discusses limitations and biomarkers
New drug combos target hidden cancer switches to stop resistance
This narrative review examines ovarian cancer management involving olaparib, bevacizumab, and durvalumab.
Hidden chemical changes in ovarian cancer cells help them hide from drugs, but new combinations might finally stop them from adapting and gr…
TP53 and PTEN mutations detected in 68% and 47% of ovarian and endometrial cancer samples respectively in a retrospective cohort
Genetic markers found in swabs may help spot ovarian and endometrial cancers
This retrospective cohort study evaluated 238 women across three tertiary hospitals between 2018 and 2023.
A new look at genetic markers in swabs shows they appear in most ovarian and endometrial cancer cases, offering a potential new way to find …
Narrative review on precision prevention for women with inherited gynecologic cancer susceptibility
New Plan Cuts Cancer Risk for High-Risk Women
This narrative review addresses ovarian, endometrial, and fallopian tube cancer in women with inherited gynecologic cancer susceptibility.
Women with strong family histories of ovarian or uterine cancer can now take smarter, personalized steps to reduce their risk — and it’s cha…
Narrative review covers adoptive cell therapy modalities for ovarian cancer
Cell therapy could stop ovarian cancer from coming back
This narrative review examines adoptive cell therapy (ACT) modalities, including tumor-infiltrating lymphocytes (TILs), chimeric antigen rec…
New immune cell treatments show promise for fighting ovarian cancer when standard drugs stop working.
Narrative review on AI and digital pathology for breast and gynecologic cancers
New AI Tools Read Tumor DNA Like a Book
This narrative review synthesizes evidence on integrating digital and molecular pathology with AI and machine learning for breast and gyneco…
Combining microscope images with genetic data gives doctors a much clearer picture of how to treat cancer patients.
Ovarian cancer diagnoses decreased during COVID-19 pandemic years at a Swiss center
Lockdowns Didn't Hurt Ovarian Cancer Survival
This retrospective cohort study of 218 patients at Bern University Hospital found primary ovarian cancer diagnoses decreased in 2020 and 202…
When the world shut down in 2020, hospitals faced a scary reality.
Narrative review links microbiome dysbiosis to gynecological cancer pathogenesis and potential therapeutic applications
Microbiome changes may help explain how gynecological cancers start and grow
This narrative review examines the role of the human microbiome in gynecological malignancies, including cervical, ovarian, endometrial, vul…
New review suggests microbiome shifts could be key to understanding gynecological cancers, opening doors for better prevention and treatment…
Meta-analysis of 11 cohort studies finds oral contraceptives associated with reduced ovarian cancer incidence
Birth Control Pills Cut Ovarian Cancer Risk — But Only If Used This Long
This meta-analysis of 11 cohort studies evaluated oral contraceptives and ovarian cancer incidence across multiple databases.
Using birth control pills for more than five years lowers ovarian cancer risk, offering a simple way to protect women from this deadly disea…
Combined albumin-lymphocyte score and skeletal muscle index linked to survival in ovarian cancer surgery patients
The Hidden Score That Could Predict Ovarian Cancer Survival
A retrospective cohort study of 347 patients with primary ovarian cancer undergoing debulking surgery found that a lower albumin-lymphocyte …
A new pre-surgery score combining blood markers and muscle mass predicts ovarian cancer survival better than either measure alone.
Plasma metabolomics panels show high discriminating power for lung, colorectal, and ovarian cancers
Blood Test Finds Unique Chemical Fingerprints for Three Major Cancers
This metabolomics biomarker discovery study analyzed plasma from 615 patients with lung, colorectal, or ovarian cancer and 95 non-cancerous …
A new blood test finds unique chemical fingerprints for lung, ovarian, and colorectal cancers with high accuracy before tumors are visible.
PARP inhibitors significantly improve progression-free survival in BRCA-mutated ovarian cancer patients
PARP Drugs Help BRCA Ovarian Cancer Patients Live Longer
This meta-analysis of 12 studies evaluated PARP inhibitor–based therapy in patients with BRCA-mutated ovarian cancer.
Women with BRCA-mutated ovarian cancer gain real survival time gains when using PARP inhibitors to delay cancer growth and stay cancer-free …
Precision oncology enables targeted therapies for gynecologic cancers, though acquired resistance remains a barrier
Precision oncology advances gynecologic cancer care but resistance remains a major barrier
This systematic review examined the current landscape of precision oncology for patients with endometrial, ovarian, and cervical carcinomas.
Molecular reclassification lets doctors use targeted drugs effectively for gynecologic cancers, but tumor evolution creates a major barrier …